Forum

Events

Partner Content

Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.